Free Newsletter
GSK allows Brits to cut H1N1 vax order by one-third
GlaxoSmithKline has agreed that the British government can cut its order of H1N1 swine flu vaccines by about a third to 34.8 million doses, which includes the doses already delivered; the deal is similar to the drugmaker's H1N1 order settlements with other countries. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: